PurMinds NeuroPharma is a neuro-medicine development and API production company. We are seeking equity capital at a significant discount to its upcoming IPO price, targeted for Q1/2024 on NASDAQ.
PurMinds has adopted a two-pronged strategy to mitigate enterprise risk via diversified revenue potentials in short, medium and long term:
- In the short term, we will achieve lasting revenue generation by leveraging special licensing and proprietary technology, producing and supplying psychedelic API and non-psychoactive nutraceuticals globally.
- Our long term goal is to create significant value by developing therapeutic solutions using Psychoactive compounds and proven traditional therapies to treat neurological disorders such as Parkinson's Disease, and Stroke recovery. We have a strategy to get to commercialization and create an impact.
Key investment highlights include:
- Experienced scientists and world-class scientific advisory board at the forefront of neuroscience advancement;
- Health Canada approved license to produce controlled substances for global supply - high barriers to entry;
- Proprietary clinical and production technology and strong IP strategy;
- Addressing unmet medical needs in a $100Bn+ market;
- In-house production capabilities using proprietary technology; and
- Opportunity to invest at substantial discount to expected IPO price.
Ready to Ask For Funding for your company?
Post a Funding Request